Business Wire

Inotrem Announces Enrollment of First Patient in its Phase IIb ASTONISH Trial for Nangibotide in the Treatment of Septic Shock

21.11.2019 10:00:00 EET | Business Wire | Press release

Share

Inotrem S.A., a biotechnology company specializing in immunotherapy for acute inflammatory syndromes, through its knowledge of the TREM-1 pathway biology, announced today it has initiated its Phase IIb ASTONISH trial to evaluate nangibotide in the treatment of septic shock and has enrolled the first patient in the trial.

Nangibotide is a TREM-1 inhibitor peptide with the potential to restore appropriate inflammatory response, vascular function, and improve post septic shock survival. Septic shock is the ultimate complication of sepsis. The incidence of septic shock continuously raises and mortality remains elevated (35%) in developed countries. There is currently no specific therapy approved for this indication besides antibiotics and supportive treatment. Inotrem’s therapeutic solution has the potential to become the first mechanism-based treatment for septic shock. Nangibotide in septic shock has been granted the fast track status in September 2019 by the FDA and the PRIME status in 2017 by the EMA.

The Phase IIb ASTONISH study aims to demonstrate the efficacy of nangibotide and bring a medically relevant proof of clinical activity in septic shock patients. In addition, this global multicentric study intends to validate a personalized medicine approach using soluble TREM-1 as potential companion diagnostic test to identify patients more likely to benefit from nangibotide treatment. The study will be conducted in 48 clinical sites across 5 European countries and the United States and will enroll a total number of 450 patients.

Jean-Jacques Garaud, CEO of Inotrem, said: “The ASTONISH trial is a Phase III enabling trial and we expect that it will generate important insights about nangibotide’s clinical activity and our personalized medicine approach in septic shock. We are enthusiastic about this study and Inotrem’s capacity to bring a first in class product in an area with major unmet medical need and to patients who today have no access to any approved treatment”.

With nangibotide, Inotrem has developed a novel approach of immunomodulation targeting the TREM-1 pathway which has the potential to address, beyond septic shock, several others acute inflammatory syndromes for which there is a major and today unsatisfied therapeutic need. Based on its its extensive knowledge of the TREM-1 pathway biology, Inotrem has aso launched a new program to expand its TREM-1 franchise into chronic inflammatory diseases

About Inotrem
Inotrem S.A. is a biotechnology company specialized in immunotherapy for acute and chronic inflammatory syndromes. The company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses. The company was founded in 2013 by Dr. Jean-Jacques Garaud, a former head of research and early development at the Roche Group, Prof. Sébastien Gibot and Dr. Marc Derive. Inotrem is supported by leading European and North American investors.
www.inotrem.com

About Nangibotide
Nangibotide is the formulation of the active ingredient LR12, which is a 12 amino-acid peptide prepared by chemical synthesis. LR12 is a specific TREM-1 inhibitor, acting as a decoy receptor and interfering in the binding of TREM-1 and its ligand. In preclinical septic shock models, nangibotide was able to restore appropriate inflammatory response, vascular function, and improved animals’ survival post septic shock. Nangibotide in septic shock has been granted the fast track status in September 2019 by the FDA.

ASTONISH Study
The Efficacy, Safety and Tolerability of nangibotide in Patients with Septic Shock (ASTONISH) phase IIb trial is a Randomized, Double-blind, Placebo Controlled Dose Selection Study that will be performed Europe and the US. Four hundred and fifty patients are planned to be included in this study in 48 clinical sites. The study will compare the effect of nangibotide at two different doses versus standard of care.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media contact for Inotrem
Anne REIN
S&I
anne.rein@strategiesimage.com
+33 6 03 35 92 05

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

AI Private Markets Platform FinBursa Appoints Angelica Tigan as Chief Revenue Officer to Drive US and Global Growth18.11.2026 15:00:00 EET | Press release

FinBursa, the intelligent front office for private markets, has appointed Angelica Tigan, a former BlackRock and eFront sales leader, as Chief Revenue Officer to lead its global commercial expansion following the launch of FinBursa 360. Based in the US, Tigan will lead sales and partnerships worldwide, with an immediate focus on the US. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118596329/en/ Angelica Tigan, based in New York City, joins FinBursa as Chief Revenue Officer Tigan brings close to two decades in private markets technology, having built, led and scaled sales teams at BlackRock (Aladdin) and eFront, with previous experience at Intralinks and Gen II Fund Services. FinBursa 360 is an all-in-one platform for private equity, private credit, real estate, venture capital and M&A advisory firms, family offices, wealth managers, placement agents and fund administrators. It brings investment CRM, deal flow and deal m

Scientist.com Launches Pharma Observatory, an Agent-First Market Intelligence Platform for Biopharma R&D18.11.2026 14:55:00 EET | Press release

Scientist.com, the leading AI-enabled R&D orchestration platform and marketplace for the life science industry, today announced the launch of Pharma Observatory, a market intelligence platform that shows biopharma teams where their programs sit in the wider market. Scientist.com helps research teams drive a project forward. Pharma Observatory places that project in context: who else is working on the same target or indication, who the likely partners and acquirers are, and what the eventual clinical trials are likely to look like. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118907460/en/ Scientist.com's Pharma Observatory brings nearly 1 billion records from ~100 public sources (ClinicalTrials.gov, FDA, USPTO, NIH, SEC) into one cross-referenced model. The public record on biopharma is huge but scattered. ClinicalTrials.gov, the FDA, SEC filings, PubMed, NIH, the USPTO and dozens of other sources each publish part of t

Helical Fusion Awarded Up to JPY 19.2 Billion in Japanese Government Funding to Accelerate Commercial Fusion Power18.11.2026 14:36:00 EET | Press release

Helical Fusion Co., Ltd., a fusion energy company developing commercially viable power plants based on Helical Stellarator technology, has been formally selected for a major Japanese government grant program administered by the Ministry of Economy, Trade and Industry (METI). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118128278/en/ The maximum government subsidy is approximately JPY 19.2 billion (USD 126 million). The grant-supported project is scheduled to run through February 2029. Through the Helix Program, Helical Fusion leads overall plant design and systems integration, drawing on research from Japan’s national research institutions and the engineering and manufacturing expertise of approximately 40 companies in Japan. The program aims to turn Japan’s scientific and industrial strengths into practical fusion power. The funding will accelerate three areas of development: Helix HARUKA: Manufacturing and assembly of

New TOURISE Report Reveals How Traveler Expectations Are Changing the Rules for Global Tourism18.11.2026 14:00:00 EET | Press release

Changing traveler priorities are reshaping global tourism, influencing where people go, how they spend and what they value most from their journeys. A new report released by TOURISE, The Future Traveller, explores these shifts and what they mean for the industry through 2030. Developed in collaboration with Euromonitor International, the report draws on consumer surveys and perspectives from industry leaders. The report finds that travel decisions are increasingly shaped by the priorities and circumstances of each trip, rather than demographics alone. It calls on destinations and businesses to rethink how they attract visitors and measure success, shifting the focus from high-spending travelers to high-value trips that deliver meaningful experiences, support local economies and create lasting benefits for communities. “Travelers are not making decisions as fixed demographic segments. They are responding to purpose, pressures and possibilities of each trip,” said His Excellency Ahmed Al

Grand Prix ACF AutoTech 2027: Applications Open for the 10th Edition18.11.2026 14:00:00 EET | Press release

The Automobile Club de France (ACF) and ESSEC Alumni are launching the 10th edition of the Grand Prix ACF AutoTech, the leading competition for automotive and mobility startups. French and international startups can apply until November 27, 2026 at 11:59 p.m. (CET) at www.grandprixacfautotech.com. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118772168/en/ Jury members and former finalist startups for the launch of 10th Edition of Grand Prix ACF AutoTech (c) Quentin Vaquez Since 2018, the competition has selected 52 finalists, including Chargemap, Hiflow, ChargeGuru and Geolith, who have together raised more than €700 million. Only 6 have failed: a survival rate of nearly 90%. The 2026 edition rewarded Altrove (Grand Prix ACF), Bloomineral (ACF Pioneer Prize and GreenTech Mention) and IoT.bzh (Industrialization Prize). “Ten editions is an achievement we are proud of. The number of applications, rising every year, shows h

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye